摘要
目的探讨利格列汀联合阿卡波糖治疗新发2型糖尿病(T2DM)患者的疗效。方法选取2018年3月至2019年3月荆州市中心医院内分泌科住院的新发T2DM患者90例,随机分成试验组(利格列汀联合阿卡波糖)和对照组(门冬胰岛素30联合阿卡波糖),每组各45例。比较两组患者各项临床指标、血糖达标时间、治疗费用以及不良反应。结果治疗后,两组空腹血糖(FBG)、餐后2 h血糖(2 h BG)、糖化血红蛋白(HbA1c)较治疗前明显下降(P<0.05),空腹胰岛素(FINS)、胰岛β细胞功能指数(HOMA-β)较治疗前明显增加(P<0.05),两组差异无统计学意义(P>0.05);对照组体重指数(BMI)较治疗前明显上升(P<0.05),试验组BMI与治疗前比较差异无统计学意义(P>0.05);两组患者血糖达标时间以及12周治疗总费用比较差异无统计学意义(P>0.05);试验组低血糖发生率4.4%,明显低于对照组的13.3%(P<0.05)。结论利格列汀联合阿卡波糖治疗新发T2DM患者疗效好,不良反应少,其临床应用价值突出。
Objective To explore the clinical efficacy of linagliptin combined with acarbose in patients with newly-diagnosed type 2 diabetes mellitus(T2DM).Methods A total of 90 patients newly diagnosed with T2DM and hospitalized in Endocrinology Department of Jingzhou Central Hospital from March of 2018 to March of 2019 were selected and randomly divided into the observation group treated with linagliptin combined with acarbose and the control group treated with insulin aspart 30 combined with acarbose,with 45 cases in each group.The clinical indicators,the time needed for blood glucose to return normal,treatment cost and adverse reactions were compared between the two groups.Results The fasting blood glucose(FBG),2h postprandial blood glucose(2hBG)and glycosylated hemoglobin(HbA1c)were significantly lower after treatment than before treatment(P<0.05).And the fasting insulin(FINS)and pancreatic islet beta cell function index(HOMA-β)were significantly higher after treatment than before treatment(P<0.05)in the two groups,but there were no significant differences between the two groups(P>0.05).The body mass index(BMI)was significantly higher after treatment than before treatment in the control group(P<0.05)and it didn't change significantly in the observation group(P>0.05).There were no significant differences in the time needed for blood glucose to return normal and the total treatment cost of 12 weeks between the two groups(P>0.05).The incidence of hypoglycemia was 4.4%in the observation group,which was significantly lower than 13.3%in the control group.Conclusion The clinical efficacy of linagliptin combined with acarbose is relatively good with less adverse reactions in treating patients with newly-diagnosed T2DM.Therefore,its clinical application value is outstanding.
作者
彭湾湾
钟雯
曾姣娥
薛君力
Peng Wanwan;Zhong Wen;Zeng Jiaoe;Xue Junli(Department of Endocrinology,Jingzhou Central Hospital, Jingzhou 434020, China)
出处
《成都医学院学报》
CAS
2020年第5期575-577,582,共4页
Journal of Chengdu Medical College
基金
湖北省自然科学基金项目(No:2017CPB736)。
关键词
利格列汀
阿卡波糖
2型糖尿病
新发
疗效
Linagliptin
Acarbose
Type 2 diabetes mellitus
Newly-diagnosed
Efficacy
